Annals of Hematology

Papers
(The TQCC of Annals of Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration69
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning50
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate50
Correction to: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders49
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia47
Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children’s Cancer Group study ALL-201546
Sufficient vitamin D is favorable for children with persistent and chronic immune thrombocytopenia43
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma41
The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction38
Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia36
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease34
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group32
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experienc31
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib29
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data29
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis27
Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience26
“In situ” MYC rearrangement and amplification as a secondary change in a case of High-grade B cell lymphoma with 11q aberration25
Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade24
Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature24
Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia22
Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature22
Advances in the ocular complications after hematopoietic stem cell transplantation22
Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies21
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma21
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multipl20
Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis19
Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients’ outcome19
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials19
Correction to: Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea19
Absence of blood donors’ anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients18
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia18
Symposium Proceedings of the international symposium ACUTE LEUKEMIAS XIX (ISALXIX), Munich March 16–19, 202518
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics18
A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia17
Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation17
Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma17
Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis16
Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants15
Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrosp15
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab15
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts15
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension15
CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study15
Maternal factors associated with iron deficiency without anaemia in early pregnancy: ECLIPSES study15
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis15
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments15
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study14
Germline mutations predispose a concurrent thymoma and diffuse large B-cell lymphoma14
Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome14
Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: 14
Basophilia and eosinophilia in polycythemia vera and essential thrombocythemia: clinical, genotype, and prognostic correlates14
Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses13
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience13
Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials13
T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults13
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives13
Primary effusion lymphoma with biphenotypic and bigenotypic features of T-cell receptor and IGH genes in an HIV-negative patient with kidney transplant13
Optimizing hemophagocytic lymphohistiocytosis screening in children: validation of the HLH-Screen score13
Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis13
Global, regional and national temporal trends in incidence and mortality of non-Hodgkin lymphoma from 1992 to 2021: an age-period-cohort analysis13
Circulating tumor DNA assisting lymphoma genetic feature profiling and identification13
Second allogeneic transplantation in relapsed acute leukemia – a risk worth taking?13
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma13
A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia12
Adipocyte fatty acid-binding protein (FABP4) as a potential biomarker for predicting metabolically driven low-grade and organ damage in thalassemia syndromes12
Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help?12
Bilateral deafness in NK/T-cell lymphoma: EBV DNA prevailed over magnetic resonance imaging12
Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis12
TGFBI regulates the TGF-β pathway to affect the malignant progression and cisplatin sensitivity in diffuse large B-cell lymphoma12
Mutational heterogeneity in large B-cell lymphoma: insights from paired biopsies12
Post-transplant lymphoproliferative disease of two different histological types12
Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture12
Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews12
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab11
Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)11
Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics11
The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria11
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma11
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma11
A novel WNK1::PDGFRB fusion gene in myeloid neoplasm with eosinophilia: a case report11
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study11
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry11
TRAF3IP3::FGFR1: a novel FGFR1 fusion identified in an aggressive case of acute myeloid leukemia11
Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with β-thalassemia10
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Inf10
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study10
Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)10
Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013–2022 in Finland10
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome10
Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through β-catenin by acting as targets of miR-495-3p10
Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review10
Sex differences in fatigue and symptoms of anemia in relation to hemoglobin level in hospitalized patients10
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)10
Identification of CD105 (endoglin) as novel risk marker in CLL10
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes10
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis10
CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression—a potential differential diagnostic pitfall between PTLD and PTSMT10
Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia10
Critical risk factors analysis of infection-associated hemophagocytic lymphohistiocytosis in children10
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide conditioning in patients with central nervous system lymphoma: a phase II study10
Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report10
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs10
Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm10
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia10
Correction to: Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese children10
An unexpected find of multifocal extranodal marginal zone lymphoma9
Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience9
Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy– a report of two cases9
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)9
Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges9
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice9
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review9
Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study9
Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective9
Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia9
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab9
Combined heterozygosity for the highly unstable variant hemoglobin Taybe, and α-thalassemia as a rare cause of hemolytic anemia9
Pseudothrombocytopenia, beyond a laboratory phenomenon: study of 192 cases9
Analytical considerations affecting plasma free haemoglobin, the haemolysis index, and correlation with clinical outcomes in sickle cell disease9
Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia9
Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia9
Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center9
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009–20209
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematol9
A cohort of allogeneic hematopoietic stem cell transplantation for pediatric rare diseases (allo-HSCT-PRD): design and preliminary results9
Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature9
Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes9
Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis9
Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura9
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors9
Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation9
Are accessory spleen screening and resection in refractory immune cytopenia an effective strategy or a waste of resources?8
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms8
Acute liver failure associated with human adenovirus infection after allogeneic hematopoietic stem cell transplantation8
Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century8
Mendelian randomization of circulating proteome identifies IFN-γ as a druggable target in aplastic anemia8
A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate8
In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation8
Post-transplant transient abnormal myelopoiesis evolving from a GATA1 mutant clone in umbilical cord blood8
Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment8
Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin’s lymphoma: A single-center prospective study8
Donor’s age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience8
Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia8
Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT8
No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey8
Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis8
Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?8
Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report8
Optimal dosage of rituximab for children with Burkitt lymphoma8
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)8
Interim PET in follicular lymphoma: more patience, please8
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome8
Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report8
miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia7
Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation7
Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments7
Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population7
Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab7
Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients7
Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study7
Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma7
Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use7
Validity of the criteria for clinical transformation of follicular lymphoma: analysis of a mostly biopsied cohort7
How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia 7
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial7
Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL)7
Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report7
Prognostic factors for patients with hematologic malignancies admitted to the intensive care unit: is allogeneic transplantation still a risk factor?7
A new score for predicting intracranial hemorrhage in patients using antiplatelet drugs7
Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia7
Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study7
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management7
Challenges in accuracy in molecular genetic diagnosis of childhood AML: case series7
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia7
Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study7
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma7
Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia7
Impact of protein-energy malnutrition on outcomes of patients with sickle cell disease: an analysis of the National inpatient sample7
Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India7
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies7
Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed7
A comparative study of platelet storage lesion in platelet-rich plasma under cryopreservation7
Validation of the simplified geriatric prognostic index in a Hellenic database of older patients (≥ 70 years old) with diffuse large B-cell lymphoma and similar disorders7
Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Cen7
Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma7
Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial7
Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings7
The experience of diagnosis and treatment for TAFRO syndrome7
Association between low incidence of TP53 mutations and reduced early relapse rates in Uygur DLBCL7
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience7
Sickle cell disease and acute leukemia: one case report and an extensive review7
Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study7
Prognostic significance of angiogenesis-associated molecules and Immunologic characteristic in elderly patients with acute myeloid leukemia7
L-DEP regimen is effective as an initial therapy for adult EBV-HLH7
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database7
Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia7
Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia7
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis7
Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants7
Clinical features and outcomes in large granular lymphocyte leukemia − associated pure red cell aplasia with STAT3 mutation7
The roles of ubiquitination in AML7
Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China7
COVID-19: impact of vaccination in myeloma patients7
Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma7
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study7
Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment7
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report7
Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia7
Analysis of PROS1 mutations and clinical characteristics in three Chinese families with hereditary protein S deficiency7
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases6
Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma6
Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation6
Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia6
Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma6
Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report6
Exploring the baseline cardiac function and its correlation with risk stratification in children diagnosed with acute lymphoblastic leukemia6
Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study6
Alectinib maintenance therapy following cord blood transplantation for relapsed pediatric anaplastic large cell lymphoma with central nervous system involvement6
Recent advances in CD5+ diffuse large B-cell lymphoma6
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory6
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma6
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation6
Real-world experience of anti-D immunoglobulin in immune thrombocytopenia6
Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-26
A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM16
Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group6
Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination6
Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases6
Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study6
The effects of complement-independent, autoantibody-induced apoptosis of platelets in immune thrombocytopenia (ITP)6
Oncology stewardship in acute myeloid leukemia6
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group6
Clinical effect of CALR allele burden in patients with essential thrombocythemia6
Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia6
Epstein-Barr virus–positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma6
T(11;14) with multiple myeloma: Standard risk survival but slow and poor response6
A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study6
Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China6
A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma6
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement6
Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study6
Speckle tracking echocardiography and β-thalassemia major. A systematic review6
Clinical features and fusion gene analysis of two Torque Teno Mini virus associated acute promyelocytic leukemia cases6
Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain6
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase6
MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway6
Impact of antithymocyte globulin on blood cyclosporin A levels in aplastic anemia patients6
Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective study6
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients6
0.30424404144287